Wellington Management Co. LLP recently announced the acquisition of new stake in Astrazeneca plc ADR (NASDAQ:AZN). The institutional investor has increased its shareholding in the Healthcare company by 0.73% to 49.49 million shares with purchase of 0.36 million shares. This fresh investment now brings its stake to 1.60% valued currently at $3.33 billion. In addition, T. Rowe Price Associates, Inc. raised its holdings by 0.63 million to 45.26 million shares. And Jennison Associates LLC has lifted its position by 5.22% or 1.14 million shares – to 22.95 million shares.
Currently, there are 3.10B common shares owned by the public and among those 3.10B shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The top 3 mutual fund holders in Astrazeneca plc ADR are Vanguard PRIMECAP Fund, Washington Mutual Investors Fund, and Vanguard Wellington Fund. Vanguard PRIMECAP Fund owns 25.81 million shares of the company’s stock, all valued at over $1.74 billion. The company bought an additional 0.14 million shares recently to bring their total holdings to about 0.83% of the shares outstanding. Washington Mutual Investors Fund sold -0.73 million shares to see its total holdings shrink to 21.73 million shares valued at over $1.46 billion and representing 0.70% of the shares outstanding. Vanguard Wellington Fund sold -0.25 million shares to bring its total holdings to over 16.82 million shares at a value of $1.13 billion. Vanguard Wellington Fund now owns shares totaling to 0.54% of the shares outstanding.
However, the script later moved the day high at 67.83, up 0.90%. The company’s stock has a 5-day price change of -3.28% and 4.22% over the past three months. AZN shares are trading -0.31% year to date (YTD), with the 12-month market performance down to -4.75% lower. It has a 12-month low price of $61.73 and touched a high of $76.56 over the same period. AZN has an average intraday trading volume of 5.46 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -0.80%, 2.37%, and -2.52% respectively.
Institutional ownership of Astrazeneca plc ADR (NASDAQ: AZN) shares accounts for 16.19% of the company’s 3.10B shares outstanding. Mutual fund holders own 7.17%, while other institutional holders and individual stakeholders account for 9.05% and — respectively.
It has a market capitalization of $208.16B and a beta (3y monthly) value of 0.54. The stock’s trailing 12-month PE ratio is 35.51, while the earnings-per-share (ttm) stands at $1.89. The company has a PEG of 2.71 and a Quick Ratio of 0.60 with the debt-to-equity ratio at 0.77. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.29% over the week and 1.22% over the month.
Analysts forecast that Astrazeneca plc ADR (AZN) will achieve an EPS of $0.8 for the current quarter, $1.01 for the next quarter and $4.3 for 2024. The lowest estimate earnings-per-share for the quarter is $0.72 while analysts give the company a high EPS estimate of $0.87. Comparatively, EPS for the current quarter was $0.69 a year ago. Earnings per share for the fiscal year are expected to increase by 9.55%, and 13.60% over the next financial year. EPS should grow at an annualized rate of 13.10% over the next five years, compared to -2.17% over the past 5-year period.
